Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 433 to 437 of 437 entries
Sorted by: Best Match Show Resources per page
Effects of Photochemical Oxidation of the Carbonaceous Additives on Li-S Cell Performance.

ACS applied materials & interfaces

Park J, Moon J, Kim K, Ri V, Lee S, Hong BH, Sung YE, Kim C, Cairns EJ.
PMID: 34428892
ACS Appl Mater Interfaces. 2021 Sep 08;13(35):41517-41523. doi: 10.1021/acsami.1c07452. Epub 2021 Aug 25.

We introduce a simple and easy way to functionalize the surface of various carbonaceous materials through the ultraviolet light/ozone (UV/O

Cite
Park J, Moon J, Kim K, et al. Effects of Photochemical Oxidation of the Carbonaceous Additives on Li-S Cell Performance. ACS Appl Mater Interfaces. 2021;13(35):41517-41523doi: 10.1021/acsami.1c07452.
Park, J., Moon, J., Kim, K., Ri, V., Lee, S., Hong, B. H., Sung, Y. E., Kim, C., & Cairns, E. J. (2021). Effects of Photochemical Oxidation of the Carbonaceous Additives on Li-S Cell Performance. ACS applied materials & interfaces, 13(35), 41517-41523. https://doi.org/10.1021/acsami.1c07452
Park, Jungjin, et al. "Effects of Photochemical Oxidation of the Carbonaceous Additives on Li-S Cell Performance." ACS applied materials & interfaces vol. 13,35 (2021): 41517-41523. doi: https://doi.org/10.1021/acsami.1c07452
Park J, Moon J, Kim K, Ri V, Lee S, Hong BH, Sung YE, Kim C, Cairns EJ. Effects of Photochemical Oxidation of the Carbonaceous Additives on Li-S Cell Performance. ACS Appl Mater Interfaces. 2021 Sep 08;13(35):41517-41523. doi: 10.1021/acsami.1c07452. Epub 2021 Aug 25. PMID: 34428892.
Copy Download .nbib Format: NLM
Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia

Caro J, Cairns D, Menzies T, Boyle E, Pawlyn C, Cook G, Kaiser M, Walker BA, Owen R, Jackson GH, Morgan GJ, Heaney J, Drayson MT, Davies FE.
PMID: 34876373
Clin Lymphoma Myeloma Leuk. 2021 Oct 18; doi: 10.1016/j.clml.2021.10.008. Epub 2021 Oct 18.

INTRODUCTION/BACKGROUND: Immunoparesis, or low polyclonal immunoglobulin levels, is commonly seen in multiple myeloma (MM), and is associated with poor clinical outcomes. MM can be divided into subgroups with distinct biology and outcomes based on etiologic cytogenetic abnormalities. These include...

Cite
Caro J, Cairns D, Menzies T, et al. Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021;doi: 10.1016/j.clml.2021.10.008.
Caro, J., Cairns, D., Menzies, T., Boyle, E., Pawlyn, C., Cook, G., Kaiser, M., Walker, B. A., Owen, R., Jackson, G. H., Morgan, G. J., Heaney, J., Drayson, M. T., & Davies, F. E. (2021). Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma. Clinical lymphoma, myeloma & leukemia, . https://doi.org/10.1016/j.clml.2021.10.008
Caro, Jessica, et al. "Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma." Clinical lymphoma, myeloma & leukemia vol. (2021). doi: https://doi.org/10.1016/j.clml.2021.10.008
Caro J, Cairns D, Menzies T, Boyle E, Pawlyn C, Cook G, Kaiser M, Walker BA, Owen R, Jackson GH, Morgan GJ, Heaney J, Drayson MT, Davies FE. Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 Oct 18; doi: 10.1016/j.clml.2021.10.008. Epub 2021 Oct 18. PMID: 34876373.
Copy Download .nbib Format: NLM
Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB.

Drug testing and analysis

Grafinger KE, Cannaert A, Ametovski A, Sparkes E, Cairns E, Banister SD, Auwärter V, Stove CP.
PMID: 33769699
Drug Test Anal. 2021 Jul;13(7):1402-1411. doi: 10.1002/dta.3035. Epub 2021 Apr 14.

Synthetic cannabinoid receptor agonists (SCRAs) are the second largest class of new psychoactive substances (NPS) and are associated with serious adverse effects and even death. Despite this, little pharmacological data are available for many of the most recent SCRAs....

Cite
Grafinger KE, Cannaert A, Ametovski A, et al. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB. Drug Test Anal. 2021;13(7):1402-1411doi: 10.1002/dta.3035.
Grafinger, K. E., Cannaert, A., Ametovski, A., Sparkes, E., Cairns, E., Banister, S. D., Auwärter, V., & Stove, C. P. (2021). Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB. Drug testing and analysis, 13(7), 1402-1411. https://doi.org/10.1002/dta.3035
Grafinger, Katharina Elisabeth, et al. "Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB." Drug testing and analysis vol. 13,7 (2021): 1402-1411. doi: https://doi.org/10.1002/dta.3035
Grafinger KE, Cannaert A, Ametovski A, Sparkes E, Cairns E, Banister SD, Auwärter V, Stove CP. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB. Drug Test Anal. 2021 Jul;13(7):1402-1411. doi: 10.1002/dta.3035. Epub 2021 Apr 14. PMID: 33769699.
Copy Download .nbib Format: NLM
Expanded practice for rural community pharmacy: what are we waiting for?.

The International journal of pharmacy practice

Taylor SM, Cairns A, Glass BD.
PMID: 34791306
Int J Pharm Pract. 2022 Jan 07;30(1):86-88. doi: 10.1093/ijpp/riab072.

OBJECTIVE: To synthesise stakeholder (consumer, pharmacist and health professional) perspectives of expanded pharmacy practice in rural and remote community pharmacy.METHODS: Comparison of perspectives of stakeholder groups identified by four studies has highlighted the expected outcomes and anticipated barriers to...

Cite
Taylor SM, Cairns A, Glass BD. Expanded practice for rural community pharmacy: what are we waiting for?. Int J Pharm Pract. 2022;30(1):86-88doi: 10.1093/ijpp/riab072.
Taylor, S. M., Cairns, A., & Glass, B. D. (2022). Expanded practice for rural community pharmacy: what are we waiting for?. The International journal of pharmacy practice, 30(1), 86-88. https://doi.org/10.1093/ijpp/riab072
Taylor, Selina M, et al. "Expanded practice for rural community pharmacy: what are we waiting for?." The International journal of pharmacy practice vol. 30,1 (2022): 86-88. doi: https://doi.org/10.1093/ijpp/riab072
Taylor SM, Cairns A, Glass BD. Expanded practice for rural community pharmacy: what are we waiting for?. Int J Pharm Pract. 2022 Jan 07;30(1):86-88. doi: 10.1093/ijpp/riab072. PMID: 34791306.
Copy Download .nbib Format: NLM
In vitro investigation of a terbinafine impregnated subcutaneous implant for veterinary use.

Journal of drug delivery

Souza MJ, Cairns T, Yarbrogh J, Cox SK.
PMID: 22888440
J Drug Deliv. 2012;2012:436710. doi: 10.1155/2012/436710. Epub 2012 Jul 19.

A terbinafine impregnated subcutaneous implant was evaluated to determine if drug was released into isotonic saline over the course of 6 months at two different temperatures, 37°C and 4°C. These temperatures were chosen to simulate the nonhibernating (37°C) and...

Cite
Souza MJ, Cairns T, Yarbrogh J, et al. In vitro investigation of a terbinafine impregnated subcutaneous implant for veterinary use. J Drug Deliv. 2012;2012:436710doi: 10.1155/2012/436710.
Souza, M. J., Cairns, T., Yarbrogh, J., & Cox, S. K. (2012). In vitro investigation of a terbinafine impregnated subcutaneous implant for veterinary use. Journal of drug delivery, 2012436710. https://doi.org/10.1155/2012/436710
Souza, M J, et al. "In vitro investigation of a terbinafine impregnated subcutaneous implant for veterinary use." Journal of drug delivery vol. 2012 (2012): 436710. doi: https://doi.org/10.1155/2012/436710
Souza MJ, Cairns T, Yarbrogh J, Cox SK. In vitro investigation of a terbinafine impregnated subcutaneous implant for veterinary use. J Drug Deliv. 2012;2012:436710. doi: 10.1155/2012/436710. Epub 2012 Jul 19. PMID: 22888440; PMCID: PMC3408648.
Copy Download .nbib Format: NLM
Showing 433 to 437 of 437 entries